Nsclc patients. Medical search. Frequent questions

Precision use of postoperative radiation therapy (PORT) may benefit patients with high tumor mutational burden (TMB) or DNA damage response and repair (DDR) mutations compared with patients who have resistant mutations. (medpagetoday.com)
The most common EGFR mutations (nearly 85%-90%) in NSCLC patients are L858R and exon 19 deletions (Ex19del), which are defined as classical mutations. (frontiersin.org)
Background: Most patients with lung cancer experience relapse, although epidermal growth factor receptor (EGFR) of tyrosine kinase inhibitor (TKI) has an astounding effect on tumors with EGFR-activating mutations. (iiarjournals.org)
A retrospective multi-institutional study analyzed the correlation between patients' survival and acquired resistance-related molecules in non-small cell lung cancer (NSCLC) samples, that possessed sensitive EGFR mutations (7 cases: exon 19 deletion, and 12 cases: exon 21 point mutation). (iiarjournals.org)
HER2 HER2 HER2 is a protein that lives on a cancer cell's surface and can be used as a target for certain cancer medicines Most HER2 mutations occur at the base of the HER2 protein inside the cell HER2 mutations play a role in promoting the growth of cancer cells 2-4% of people with NSCLC have HER2 mutations. (studylib.net)
Smoking histories HER2 mutations can occur in a range of people with NSCLC, and the cause of these mutations is unknown NSCLC, non-small cell lung cancer. (studylib.net)
However, an article published in Targeted Oncology states that only 3-7% of NSCLC cases result from mutations or rearrangements in the anaplastic lymphoma kinase genes. (patientworthy.com)
So, anaplastic lymphoma kinase-positive NSCLC is a type of lung cancer caused by ALK genetic mutations. (patientworthy.com)
An interview with Dr. Gregory Masters discussing the latest guidelines treating non-small cell lung cancer (NSCLC) with gene mutations. (lcfamerica.org)
The most important components of this updated guideline confirm that osimertinib is the best first-line option for patients with standard activating EGFR mutations , such as L858R and deletion 19 mutations. (lcfamerica.org)
In general, for the additional mutations you mention, we recommend treatment according to the other NSCLC guideline for patients without driver mutations. (lcfamerica.org)
Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with NSCLC without EGFR, ALK, and ROS gene mutations. (biomedcentral.com)
Objective: Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon EGFR mutations remain insufficient. (umn.edu)
This study aimed to investigate the effect of first-line EGFR-TKIs or platinum-based chemotherapy in NSCLC patients with uncommon EGFR mutations. (umn.edu)
Results: Seventy patients (13.9%) harboring uncommon EGFR mutations were included. (umn.edu)
Multivariate analyses identified adenocarcinoma (P=0.003) as the independent predictive factor for PFS in patients with uncommon EGFR mutations who were treated with first-line EGFR-TKIs. (umn.edu)
Furthermore, a concordance rate of 82% between cobas and the NGS approach for the EGFR sensitizing mutations (in exons 18, 19, 21) was observed in patients with acquired resistance to EGFR TKIs, while this concordance was 94% for the p.T790M mutation, with NGS being able to detect this mutation in three 3 additional patients. (bioncology.gr)
The use of new sensitive NGS techniques can reliably detect tumor-derived mutations in liquid biopsy and provide clinically relevant information both before and after targeted treatment in patients with NSCLC. (bioncology.gr)
First-generation EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). (researchgate.net)
The third-generation EGFR TKIs selectively and irreversibly target EGFR T790M and activating EGFR mutations, showing promising efficacy in NSCLC resistant to the first- and second-generation EGFR TKIs. (researchgate.net)
Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. (researchgate.net)
In this review, we summarize the available post-progression therapies including third-generation EGFR inhibitors and combination treatment strategies for treating patients with NSCLC harboring EGFR mutations and address the known mechanisms of resistance. (researchgate.net)
The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations. (news-medical.net)
Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy. (cdc.gov)

The study showed that atezolizumab significantly improved overall survival and resulted in a clinically meaningful long-term survival benefit, with twice as many patients (24%) who were treated with atezolizumab remaining alive at two years compared to those treated with chemotherapy (12%), despite over 50% of chemotherapy patients who were still alive at two years receiving subsequent immunotherapy. (news-medical.net)

9 July 2023 https://patents.google.com/patent/US9012462B2/en. (wikipedia.org)

However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to the combination of afatinib and chemotherapy. (frontiersin.org)
EGFR G724S mutation in exon 18 is a rare driver mutation, only found in about 0.3%-0.8% of NSCLC patients. (frontiersin.org)
Seventy-five percent of G724S-positive patients harbored a concurrent mutation of exon 19 del and insertions ( 2 ). (frontiersin.org)
Plasma or cerebrospinal fluid samples of these patients were then sequenced after treatment using a 139-lung-cancer-gene capture-based targeted panel (Geneseeq), aiming to comprehensively profile their concurrent mutation statuses and explore the potential resistance mechanisms in G724S-positive patients. (frontiersin.org)
Subgroup of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) benefitted from the addition of necitumumab to gemcitabine plus cisplatin. (cancertherapyadvisor.com)
The subgroup of patients with epidermal growth factor receptor ( EGFR ) mutation-positive advanced squamous non-small cell lung cancer (NSCLC) benefitted from the addition of necitumumab to gemcitabine plus cisplatin, a late-breaking study presented at the European Lung Cancer Conference (ELCC) 2016 has shown. (cancertherapyadvisor.com)
Non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. (studylib.net)
For instance, stage IV NSCLC and MET exon 14 skipping mutation may be treated with MET -targeted therapy - capmatinib (Tabrecta) or tepotinib (Tepmetko) - in the first-line setting, while for patients with stage IV NSCLC and driver alterations in RET, first-line setting, selpercatinib (Retevmo) is an option. (lcfamerica.org)
RESULTS: At least one mutation was identified in almost 49% of the cases by the NGS approach in NSCLC patients analyzed at diagnosis. (bioncology.gr)
However, after a median duration of response of ~12 months, all patients develop tumor resistance, and in over half of these patients this is due to the emergence of the EGFR T790M resistance mutation. (researchgate.net)
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? (hindawi.com)
We analyzed whole-genome sequencing data from 2,511 individuals in the Pan-Cancer Analysis of Whole Genomes (PCAWG) study as well as 489 individuals from four prospective cohorts and found distinct regional mutation type-specific frequencies in tissue and cell-free DNA from patients with cancer that were associated with replication timing and other chromatin features. (nature.com)
He explained that the focus of the company's VS-6766 and defactinib NSCLC development program on G12V mutation is unique and it represents a massive step forward in understanding how to deliver better treatment to mutant NSCLC patients. (biopharmajournal.com)
Additionally, the T790M "gatekeeper" mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors. (wikipedia.org)
A Canadian clinical guideline publication recommends liquid biopsy being performed first for the detection of EGFR T790M mutation in patients with EGFR sensitizing mutation-positive NSCLC who progress on first- or second-generation EGFR TKI therapy, followed up with tissue biopsy if the liquid biopsy is negative for T790M. (cdc.gov)
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation - Study of MRTX849 vs Docetaxel in Pts With Advanced NSCLC KRAS G12C Mut. (who.int)

A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy. (news-medical.net)
For the fittest patients with advanced stage NSCLC, first-line immunotherapy with or without platinum-based doublet chemotherapy (PDC) is now established as the standard of care treatment. (news-medical.net)
Sponsored by Roche, this is the first reported randomized phase III trial of first-line immunotherapy treatment with atezolizumab (also known as Tecentriq) in an advanced NSCLC population deemed unfit for standard platinum-chemotherapy. (news-medical.net)
The trial sought to establish the efficacy , safety and overall survival rate of first-line immunotherapy treatment with atezolizumab compared with single-agent chemotherapy in advanced stage NSCLC patients. (news-medical.net)
IPSOS is the first randomised trial to show that immunotherapy treatment with first-line atezolizumab treatment significantly improves overall survival compared to single-agent chemotherapy for these poor prognosis patients, with twice as many remaining alive at two years. (news-medical.net)
Pembrolizumab monotherapy is a standard of care in patients with immunotherapy-naive or previously treated, PD-L1-positive advanced non-small cell lung cancer," Dr. Roy S. Herbst, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, and associate cancer center director for translational research at Yale Cancer Center, said during a virtual presentation of the follow-up results. (curetoday.com)
Recent approvals of immunotherapy agents for adjuvant and neoadjuvant therapy may support wider use among patients with non-small cell lung cancer treated with pneumonectomy. (medpagetoday.com)
In our retrospective study published in JCO Oncology Practice , 3 we investigated the proportion of ED visits by patients with NSCLC that were attributable to the cancer versus its medical therapies: TKI therapy, immune-checkpoint inhibitor immunotherapy, and cytotoxic chemotherapy. (ilcn.org)
Using the STAnford medicine Research data Repository (STARR), we identified 173 ED visits in 2018 made by 97 patients with NSCLC who had received TKI therapy, immunotherapy, or chemotherapy within the 3 months before their ED visit. (ilcn.org)
A retrospective study found no additional benefit for patients with non-small cell lung cancer who continued immunotherapy beyond 2 years. (targetedonc.com)
In patients with non-small cell lung cancer (NSCLC) who were progression-free on immunotherapy (IO) at 2 years, 1 in 5 discontinued their treatment. (targetedonc.com)
This observational study is 1 piece of data that may provide reassurance to providers and patients who wish to stop at 2 years, showing that this strategy does not appear to lead to worse survival compared to continuing immunotherapy. (targetedonc.com)
90% of patients taking immunotherapy have no side effects at all! (cancer.org)
I was put on immunotherapy and was told it is used for all forms of NSCLC and now SCLC. (cancer.org)

Patients treated with radiationtherapy alone had similar nodal stage distribution, but somewhatsmaller tumors. (cancernetwork.com)
In August 2016, KEYTRUDA (pembrolizumab) (2 mg/kg every three weeks) was approved in Europe for previously-treated patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 (TPS of 1 percent or more) and who have received at least one prior chemotherapy regimen. (merck.com)
The data demonstrate that KEYTRUDA provided meaningful improvements in survival versus the current standard of care in patients whose tumors express high levels of PD-L1," said Dr. Luis Paz-Ares, chair of the medical oncology department, Hospital Universitario Doce de Octubre, Madrid, Spain. (merck.com)
In a demonstration of vaccine therapy's potential for treating lung cancer, scientists report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). (scienceblog.com)
In addition to being the largest data set of lung cancer patients treated with this type of drug, this is the first independent validation that PD-L1 expression in tumors is clearly a marker of response," said Garon. (oncnursingnews.com)
Methods This sub-analysis aimed to assess long-term overall survival (OS) data of patients with NSCLC whose tumors are EGFR wild-type or who have unknown EGFR mutational status and were tested with the HIC at the CHRISTUS St. Frances Cabrini Cancer Center ( NCT03289780 ). (bmj.com)
Of the 982 patients who participated in SQUIRE, 95% had EGFR -expressing tumors and 5% did not. (cancertherapyadvisor.com)
Patients with no EGFR in their tumors experienced no benefit from the addition of necitumumab. (cancertherapyadvisor.com)
We cannot make robust conclusions because the subgroup of patients with negative EGFR was very small, but the hypothesis generated here is that those tumors do not respond well to necitumumab. (cancertherapyadvisor.com)
Dr Paz-Ares noted that a confirmatory study in patients with EGFR -negative tumors is necessary to evaluate whether they are appropriate candidates for necitumumab or not. (cancertherapyadvisor.com)
Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (cancertherapyadvisor.com)
Some patients, as the disease progresses, may also experience malignant brain tumors. (patientworthy.com)
29% of patients had brain tumors, and 26% of patients previously received chemotherapy. (patientworthy.com)
As compared to Group 1, 30% of Group 2 patients had brain tumors. (patientworthy.com)
After two years of follow-up, researchers discovered that ALUNBRIG reduced the rate of disease progression and death by between 69-76% for patients with brain tumors. (patientworthy.com)
The data support the combination of pembrolizumab and chemotherapy as a ﬁrst-line treat-ment for metastatic squamous NSCLC in patients with PD-L1‒positive and PD-L1‒negative tumors. (bpno.no)
Methods: Escalating doses of PF-04691502 were administered to 23 patients with advanced solid tumors in sequential cohorts across the following dose levels: 2 mg, 4 mg, 8 mg, and 11 mg. 14 additional patients were enrolled in an expansion cohort at the MTD to ensure at least five matched pre- and post-treatment biopsies for biomarkers of PI3K activity. (researchgate.net)
CMS coverage has been approved under specific clinical scenarios for liquid biopsy for patients with lung cancer , as well NSCLC, colorectal, breast, and other solid tumors . (cdc.gov)
Stereotactic body radiotherapy (SBRT) may be used in early-stage NSCLC tumors that are smaller than 5 cm without lymph node involvement. (medscape.com)

In AURA3 ( NCT02151981 ), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. (nih.gov)
In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum-pemetrexed, which possibly reflects the high crossover rate of patients from platinum-pemetrexed to osimertinib. (nih.gov)
The 5-year survival rate of patients with and without T790M was 86.7% and 13.3%, respectively (p=0.020). (iiarjournals.org)
Although they exhibited promising anti-T790M activity in the laboratory, their clinical activity among T790M+ NSCLC was poor mainly because of dose-limiting toxicity due to simultaneous inhibition of wild-type EGFR. (researchgate.net)
Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. (researchgate.net)
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. (bvsalud.org)
Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small- cell lung cancer (NSCLC). (bvsalud.org)
Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI treatment , received once-daily osimertinib 80 mg. (bvsalud.org)
Second-/later-line osimertinib demonstrated real-world clinical benefit and safety in advanced/metastatic EGFR T790M NSCLC. (bvsalud.org)

The trial results, published today in The Lancet , are good news for non-small cell lung cancer patients who are not eligible for standard of care platinum-based chemotherapy, due to concerns about their ability to withstand the treatment. (news-medical.net)
The addition of cisplatin (Platinol) and oral etoposide (VePesid)to radiation therapy delays distant metastasis, thus increasingsurvival of patients with inoperable non-small-cell lung cancer,a comparison of RTOG 91-06 to RTOG 83-11 shows. (cancernetwork.com)
Patients treated with combined therapy had either stage IIIa orIIIb or medically inoperable stage II non-small-cell lung cancer.They were given 50 mg/m² of cisplatin on days one and eightof treatment. (cancernetwork.com)
Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy. (cancernetwork.com)
The approval of KEYTRUDA as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated," said Dr. Roy Baynes, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories. (merck.com)
In patients with lung cancer, sequencing bronchoalveolar lavage (BAL) cell-free DNA is more sensitive for identifying genomic alterations than sequencing plasma cell-free BAL and may provide an alternative for diagnostic and molecular profiling when tissue specimens are limited. (medpagetoday.com)
Swedish investigators compared response to first-line immune checkpoint blockade (ICB) and platinum doublet chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). (medpagetoday.com)
Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the standard first-line treatment for advanced EGFR -mutated non-small cell lung cancer (NSCLC). (frontiersin.org)
In this study, we reported two patients with EGFR Ex19del/G724S lung cancer who appeared in remission after being treated with afatinib and chemotherapy. (frontiersin.org)
A 47-year-old Chinese female patient without a smoking history was preliminarily diagnosed with right lung cancer with suspected multiple liver and bone metastasis. (frontiersin.org)
Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1-positive advanced non-small cell lung cancer. (curetoday.com)
Keytruda (pembrolizumab) continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1-positive advanced non-small cell lung cancer (NSCLC) after more than five years of follow-up, according to results from the phase 2/3 KEYNOTE-010 study presented at the 2020 World Conference on Lung Cancer. (curetoday.com)
In a cohort study reported in JAMA Network Open , Wang et al found that overall survival in patients with non-small cell lung cancer (NSCLC) who stopped smoking prior to their cancer diagnosis was better than overall survival among those who were current smokers at the time of their diagnosis. (ascopost.com)
The study involved patients with NSCLC who were recruited to the Boston Lung Cancer Survival Cohort at Massachusetts General Hospital between 1992 and 2022. (ascopost.com)
The investigators concluded, "In this cohort study of patients with NSCLC, quitting smoking early was associated with lower mortality following a lung cancer diagnosis, and the association of smoking history with overall survival may have varied depending on clinical stage at diagnosis, potentially owing to the differing treatment regimens and efficacy associated with smoking exposure following diagnosis. (ascopost.com)
The goal of this activity is for learners to have greater awareness about the importance of broad-based molecular testing in treatment decision-making for patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). (medscape.org)
In a U.S. cohort study reported in JAMA Oncology , Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non-small cell lung cancer (NSCLC) has been associated with "modest" improvements in overall survival, particularly among older patients. (ascopost.com)
Molecular-targeted drug therapy has been promoted because the selection of patients by genetic markers can increase the therapeutic response for patients with non-small cell lung cancer (NSCLC) ( 1 ). (iiarjournals.org)
Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases. (scienceblog.com)
Pembrolizumab (Keytruda) had an overall response rate (ORR) of 45.2% among a cohort of patients with high PD-L1-expressing nonâ€"small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial. (oncnursingnews.com)
These results have the potential to substantively change the way that lung cancer is treated," said lead author, Edward Garon, MD. "The effectiveness of pembrolizumab in treating patients with NSCLC and the prolonged duration of their responses is quite exciting," added Garon, who is medical director of Thoracic Oncology at UCLA's Jonsson Comprehensive Cancer Center. (oncnursingnews.com)
MK-3475) and validation of PD-L1 expression as a biomarker in patients (pts) with non-small cell lung cancer (NSCLC): findings from KEYNOTE-001. (oncnursingnews.com)
Chemoresistance is a significant barrier to the treatment and management of non-small cell lung cancer (NSCLC). (dovepress.com)
4 As the primary type of lung cancer, non-small cell lung cancer (NSCLC) exhibits multiple histological types, such as bronchoalveolar carcinoma, large cell carcinoma, squamous cell carcinoma, and adenocarcinoma. (dovepress.com)
[ 1 ] The USPSTF recommends discontinuing screening once 15 years have gone by since the patient stopped smoking, or if the patient develops a health problem that "substantially limits life expectancy or the ability or willingness to have curative lung surgery. (medscape.com)
The NCCN advises that patients are not eligible for lung cancer screening if they have symptoms of lung cancer, a past history of lung cancer, or functional status and/or comorbidity that would prohibit curative intent treatment. (medscape.com)
None of the guidelines recommend using chest radiography or sputum cytology to screen asymptomatic patients for lung cancer. (medscape.com)
The guideline set of more than 275 recommendations includes an executive summary of current recommendations for diagnosis and treatment, along with additional recommendations for screening, chemoprevention and treatment of tobacco use in patients with lung cancer. (medscape.com)
On November 6, 2017, the Food and Drug Administration granted regular approval to alectinib (ALECENSA, Hoffmann-La Roche, Inc./Genentech, Inc.) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (fda.gov)
Non-small cell lung cancer (NSCLC) is the most common lung cancer. (macmillan.org.uk)
Non-small cell lung cancer not otherwise specified (NOS) is when the expert doctor in cell types (pathologist) cannot say for certain which type of NSCLC it is. (macmillan.org.uk)
Purpose: The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in the treatment of patients with advanced non-small cell lung cancer (NSCLC). (uniroma1.it)
A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoural heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping. (ecancer.org)
MET exon 14 skipping, as a rare driver for non-small cell lung cancer (NSCLC), can be successfully targeted by MET specific tyrosine kinase inhibitors (TKI) like savolitinib, tepotinib, and capmatinib. (ecancer.org)
According to a release on Biospace , the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) who were not treated by any ALK inhibitor in the past. (patientworthy.com)
A year ago, ASCO released a clinical practice guideline on systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. (lcfamerica.org)
In fact, there is an NCI clinical trial that attempts to address sequencing of therapy for patients with advanced non-small cell lung cancer with ALK alterations: "NRG LU-003: Biomarker driven protocol for previously treated ALK positive non-squamous non-small cell lung cancer patients. (lcfamerica.org)
2 When patients with lung cancer present to the emergency department (ED), the root cause is often presumed to be either the cancer or its therapy, but there is a lack of data on this topic. (ilcn.org)
These findings suggest that a significant portion of unplanned hospital care for patients with lung cancer might be managed with early intervention, extension of ambulatory care services, and patient and provider education regarding the various available avenues of urgent care. (ilcn.org)
This study will seek to investigate the efficacy of "Microbiota modulation of the Gut-Lung Axis" combined with chemotherapy in patients with advanced NSCLC. (biomedcentral.com)
Based on the theoretical basis of "intestinal and lung axis microecological adjustment", combined with traditional platinum-containing two-drug chemotherapy, the efficacy of the new therapy on patients with advanced NSCLC was observed. (biomedcentral.com)
This study explores the combination of intestinal microecological regulation and chemotherapy to provide new treatment strategies and basis for lung cancer patients. (biomedcentral.com)
It can help prolong the survival time of lung cancer patients and improve the quality of life, thereby generating huge economic and social benefits. (biomedcentral.com)
Among the kinds of lung cancer, non-small cell lung cancer (NSCLC) accounts for about 85% of the total number of lung cancers. (biomedcentral.com)
BACKGROUND: Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy. (bioncology.gr)
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced. (targetedonc.com)
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant non-small-cell lung cancer (NSCLC). (researchgate.net)
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer (NSCLC) patients have been under debate for many years. (sense-studios.com)
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. (sense-studios.com)
AZN - Free Report ) Tagrisso (osimertinib) for patients with late-stage non-small cell lung cancer (NSCLC). (zacks.com)
90% of patients with lung cancer, including those with stage I and II disease. (nature.com)
Verastem Inc. (NASDAQ:VSTM) has announced the commencement of a second phase registration-directed clinical study of VS-6766 in patients with KRAS mutant non-small cell lung cancer (NSCLC). (biopharmajournal.com)
Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. (wikipedia.org)
Surgery is recommended for patients with stage I or II non-small cell lung cancer NSCLC) and may provide the best possibility for a cure. (medscape.com)
which demonstrated greater rep-resentation of the bronchioalveolar carcinoma subtype and improved survival after non–small cell lung cancer (NSCLC) among US-born and foreign-born Hispanics compared with non-Hispanic whites, has already begun to change the dialogue and inform future research and potential clinical implications regarding the biology and prognosis of NSCLC among Hispanic patients. (cdc.gov)
Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. (medscape.com)
We aimed to comprehensively characterise the spatial immune phenotypes in the mutational and clinicopathological background of non-small cell lung cancer (NSCLC). (lu.se)
Using SAS- based text mining, the CalCARES Program developed an algorithm to extract specific systemic treatment information for stage IV non-small cell lung cancer (NSCLC) from the free-text treatment text fields. (cdc.gov)

The 2-year survival of patients who were treated with chemotherapyand radiation therapy was 36%, said Dr. Ritsuko Komaki, co-chairof RTOG 91-06. (cancernetwork.com)
Treated with afatinib combined with chemotherapy, both patients responded well and achieved progression-free survival. (frontiersin.org)
According to the public cases, five patients with Ex19del/G724S treated with afatinib monotherapy achieved an average of only four months of progression-free survival (PFS)(2). (frontiersin.org)
In the KEYNOTE-010 trial, treatment with Keytruda significantly improved overall survival (the period of time patients on a trial are still alive after they are diagnosed or started treatment) and progression-free survival (the time from treatment to disease progression or worsening). (curetoday.com)
In the five-year follow-up, the agent continued to significantly improve overall and progression-free survival, compared with docetaxel, in patients with a PD-L1 Tumor Proportion Score (TPS) of 50% or greater and a PD-L1 TPS of 1% or greater. (curetoday.com)
Median overall survival was also superior with Keytruda in patients with a PD-L1 TPS of 50% or greater (16.9 months versus 8.2 months) and a PD-L1 TPS of 1% (11.8 months versus 8.4 months), compared with docetaxel. (curetoday.com)
However, corresponding survival gains were modest, particularly in the oldest patients. (ascopost.com)
The 5-year overall survival (OS) rate for patients with overexpresion and for those with weak expression of HGF was 75.0% and 22.2%, respectively (p=0.259). (iiarjournals.org)
On the other hand, the patients with weak HGF expression and EMT change tend to have a poor survival. (iiarjournals.org)
Survival data were also presented at AACR for 356 patients in the total population whose PD-L1 levels were evaluable by the CTA. (oncnursingnews.com)
Future analyses of the larger trial population across multiple sites will provide further information as to the long-term survival of patients tested with the HIC and the treatment patterns by physicians after receiving test results. (bmj.com)
In this study, we demonstrated that NSCLC-derived CAFs were innately resistant to cisplatin treatment and CAFs-conditioned medium significantly promoted the survival rate of NSCLC cells after cisplatin treatment. (dovepress.com)
5 To date, platinum-based chemotherapy is the most effective therapy to treat advanced NSCLC patients, 6 with a significantly higher survival and response rate. (dovepress.com)
For patients where response is important, you really double that response rate, but also you get an improvement in median progression-free survival by, again, 2-3 months. (medscape.com)
The phase 3 SQUIRE trial demonstrated that adding necitumumab to gemcitabine-cisplatin chemotherapy improved overall survival by 1.6 months in patients with stage 4 squamous NSCLC as compared with chemotherapy alone. (cancertherapyadvisor.com)
Moreover, there was a lack of overall survival (OS) benefit for these patients, supporting the discontinuation of IO at the 2-year mark. (targetedonc.com)
To investigate the optimal duration of IO in patients with NSCLC, Sun et al utilized a United States (US) oncology database (Flatiron) to assess treatment patterns and survival outcomes correlating with discontinuation of 2-year immune checkpoint inhibitor (ICI) therapy. (targetedonc.com)
In one study, Kathy Han, M.D., of the Princess Margaret Cancer Center at the University of Toronto, and colleagues found that liquid biopsy tests looking at persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) following chemoradiotherapy (CRT) can accurately identify inferior progression-free survival in patients with cervical cancer. (msdmanuals.com)
Saeed et al examined survival after NSCLC among US-born and non–US-born Hispanics compared with non-Hispanic whites using population-based data from the Surveillance, Epidemiology, and End Results (SEER) 17-registry database. (cdc.gov)
Furthermore, survival outcomes by specific treatment type extend knowledge about the effectiveness of drug regimens among all patients, not just those eligible for clinical trials. (cdc.gov)

In December 2015, alectinib received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant of crizotinib based on an independent review committee (IRC)-assessed overall response rate (ORR) of 38% and 44% among 87 and 138 patients, respectively, in two single arm trials. (fda.gov)

Current National Comprehensive Cancer Network (NCCN) 2022 guidelines specific to NSCLC (V5.2022) advise plasma cell-free/circulating tumor DNA testing should not be used in lieu of histologic tissue diagnosis, although it can be considered in specific clinical circumstances (i.e., if a patient is not suitable for invasive tissue sampling, if insufficient material following pathologic confirmation or incomplete assessment of all recommended biomarkers in the initial diagnostic setting). (cdc.gov)

Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum-pemetrexed) intravenously, every 3 weeks (≤6 cycles). (nih.gov)
Patients could crossover to osimertinib on progression confirmed by blinded independent central review. (nih.gov)
A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum-pemetrexed (136 received treatment). (nih.gov)
15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum-pemetrexed had died. (nih.gov)
At DCO, 99/136 (73%) patients in the platinum-pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. (nih.gov)
It has been reported that the presence of Ex19del reduced osimertinib-binding affinity to EGFR in vitro ( 3 , 4 ), whereas it retained sensitivity to afatinib, suggesting a possible therapy for patients ( 3 ). (frontiersin.org)
Results from ASCO 23 provide confidence that adjuvant osimertinib should be considered the standard of care for patients with resected EGFRm stage IB-IIIA NSCLC. (bpno.dk)

The study used Flatiron Health database data from approximately 280 predominantly community-based cancer clinics on patients aged ≥ 18 years diagnosed with stage IIIB, IIIC, or IV NSCLC between January 2011 and December 2019. (ascopost.com)
Any long term survivors of stage IIIb or stage IV NSCLC? (cancer.org)
I would be interested in hearing from long-term survivors of stage IIIb and stage IV NSCLC. (cancer.org)

Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. (iaslc.org)
9 , 10 As such, it is urgent to improve the efficacy of chemotherapy to NSCLC and explore the molecular mechanism underlying cisplatin resistance of NSCLC. (dovepress.com)
Recent clinical trials of MET selective TKIs displayed encouraging clinical efficacy but nearly half of NSCLC patients with MET exon 14 skipping did not benefit from MET-TKI treatment, which indicated biological heterogeneity in NSCLCs driven by METex14 skipping. (ecancer.org)
This approach aims to evaluate the toxicity profiles, efficacy and other endpoints among patients with different eligibility criteria. (zacks.com)
The study will evaluate VS-6766's safety and efficacy alone or in combination with defactinib in KRAS mutant NSCLC patients, after a platinum-based regimen and immune checkpoint inhibitor treatment. (biopharmajournal.com)

To improve knowledge of current standards and future candidates of perioperative therapy to promote better outcome in patients with resectable NSCLC. (iaslc.org)

Treatment with standard PDC is not suitable for many of these patients because of poor tolerance or toxicity concerns, leaving them with limited treatment options. (news-medical.net)
The rates of life-threatening nonhematologic toxicity were similarfor both groups of patients (2.6% for the combined treatment;3.0% for radiation therapy alone). (cancernetwork.com)
Three patients in the combined group had treatment- related deaths(two pulmonary and one renal). (cancernetwork.com)
We are committed to ensuring that patients in Europe - who are in need of new treatment options - are able to quickly gain access to KEYTRUDA. (merck.com)
These findings supporting the approval also provide further rationale for biomarker testing in order to identify those patients more likely to benefit the most from treatment with KEYTRUDA. (merck.com)
The European Commission's approval is based on data from KEYNOTE-024, a randomized, open-label, phase 3 study evaluating KEYTRUDA monotherapy at a fixed dose of 200 mg compared to standard of care platinum-containing chemotherapy (pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or paclitaxel+carboplatin) for the treatment of patients with both squamous and non-squamous metastatic NSCLC. (merck.com)
Our study lends credence to treatment using afatinib combined with chemotherapy as a viable option for patients with Ex19del/G724S. (frontiersin.org)
The analysis included patients who completed Keytruda treatment or stopped treatment after experiencing a complete response. (curetoday.com)
In addition, patients who received Keytruda for six months or more could also receive a second course with the drug for up to one year after their disease progressed when they stopped their initial treatment. (curetoday.com)
In addition, patients who completed 35 cycles of Keytruda treatment demonstrated durable clinical benefit, with an overall response rate of 98.7%, which included 15 complete responses and 63 partial responses. (curetoday.com)
Lastly, 21 patients received a second course of Keytruda after their disease progressed following the first round of treatment. (curetoday.com)
However, despite an initial response to treatment with EGFR-TKIs in specific patients, the majority of patients eventually experience a progression of their disease ( 2 , 3 ). (iiarjournals.org)
The KEYNOTE-001 trial included 495 previously treated and treatment-naïve patients with advanced or metastatic NSCLC. (oncnursingnews.com)
In March, the FDA approved nivolumab (Opdivo) for the treatment of patients with advanced squamous NSCLC who have progressed on or after platinum-based chemotherapy. (oncnursingnews.com)
Neither the drug nor the biomarker test [used in KEYNOTE-001] is approved for use in this setting at this time, but if I had a patient whose tumor had PD-L1 expression on at least half of the cells and if pembrolizumab was available, I think that I would find the data compelling to look at the drug as the treatment option for that patient. (oncnursingnews.com)
The test stratifies patients into two groups, HIC-H and HIC-C and helps evaluate patient prognosis and response to treatment. (bmj.com)
Necitumumab is an EGFR antagonist approved by the U.S. Food and Drug Administration for the first-line treatment of patients with metastatic squamous NSCLC in combination with gemcitabine and cisplatin. (cancertherapyadvisor.com)
They are currently completing a number of trials on TAK-788, an EGFR/HER2 inhibitor, for the treatment of patients with NSCLC. (patientworthy.com)
Prior to this approval, ALUNBRIG received Accelerated Approval in 2017 from the U.S. Food and Drug Administration to treat patients with anaplastic lymphoma kinase-positive NSCLC who were not responding to crizotinib treatment. (patientworthy.com)
It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of patients with ALK+ NSCLC, as well as Orphan Drug Designation for the treatment of ALK+ NSCLC, ROS1+ NSCLC, and EGFR+ NSCLC. (patientworthy.com)
This randomized, open-label, multi-center trial followed 275 patients with anaplastic lymphoma kinase-positive NSCLC who had not received prior ALK inhibitor treatment. (patientworthy.com)
Did that come as a surprise to you and your fellow panel members given the rapid expansion of the NSCLC treatment armamentarium? (lcfamerica.org)
Treatment of patients with ALK alterations has become quite complex, with multiple new drugs and not enough comparative trials in a unique population. (lcfamerica.org)
Therefore the treatment of advanced NSCLC remains a significant medical need. (biomedcentral.com)
The clinical characteristics and treatment outcomes were collected and compared between patients with common and uncommon EGFR-mutant NSCLC. (umn.edu)
Little is known about the appropriate treatment duration of IO in the NSCLC population. (targetedonc.com)
In clinical trials, duration of treatment with IO for patients with NSCLC was capped at 2 years or a maximum of 35 cycles administered every 3 weeks. (targetedonc.com)
As more patients with NSCLC are reaching the 2-year mark of IO, whether to continue or stop treatment is an increasingly common clinical question that providers and patients are grappling with. (targetedonc.com)
The difference between long-term ICI use in patients who discontinued treatment at the 2-year mark was compared with those who continued ICI beyond 2 years. (targetedonc.com)
Results showed that of the 14406 patients who began frontline IO therapy, 1091were still on treatment at 2 years. (targetedonc.com)
Although 1 in 5 patients with NSCLC discontinued treatment in the absence of associated progression or death within 2 months, the study showed that rates of ICI discontinuation were not substantially higher at 2 years than at other time points. (targetedonc.com)
Additionally, a comparative analysis of NSCLC patients at relapse following EGFR Tyrosine Kinase Inhibitor (TKIs) treatment was performed in 50 patients by both the cobas and NGS platforms. (bioncology.gr)
CONCLUSIONS: This study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized treatment decision making. (bioncology.gr)
Mark Socinski, MD, and Joshua Sabari, MD, discuss the treatment options for patients with KRASG12C mutated NSCLC with CNS metastases, and share advice for community oncologists treating this population. (targetedonc.com)
Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anti-cancer therapy and/or died. (stanford.edu)
In these patients tumor assessment would continue as per the schedule of assessments until treatment with LDK378 was permanently discontinued. (stanford.edu)
Tagrisso is already approved for the treatment of NSCLC. (zacks.com)
MRK - Free Report ) Keytruda for late-stage NSCLC patients who have progressed after Keytruda treatment. (zacks.com)
It merely helped patients live an extra year (and of course the treatment itself lasts a year). (cancer.org)
In 2016, brigatinib was granted orphan drug status by the FDA for treatment of NSCLC. (wikipedia.org)
citation needed] In 2020, it was approved as first-line treatment for ALK-positive metastatic NSCLC patients. (wikipedia.org)
HPV ctDNA testing can identify, as early as at the end of CRT, cervical cancer patients at high risk of recurrence or future treatment intensification trials," Han said. (msdmanuals.com)
Patients who have often gone through months of treatment prior to radiation, can safely undergo three instead of five weeks of postmastectomy radiation and have similar outcomes," Wong said. (msdmanuals.com)
In the multi-institutional phase II study TransTasman Radiation Oncology Group FASTRACK II, Shankar Siva, Ph.D., of the Peter MacCallum Cancer Centre and the University of Melbourne in Australia, and colleagues found that high-dose radiation is an effective treatment option for older patients with kidney cancer who are ineligible for surgery. (msdmanuals.com)
In this study, the authors enrolled patients who were unable or unwilling to undergo surgery and tested a novel therapy -- stereotactic ablative body radiotherapy (SABR) -- as a curative treatment option. (msdmanuals.com)
Patients randomized to the comparator arm will receive treatment with docetaxel. (who.int)
Registry has specific treatment information for patients in an unstructured free-text format. (cdc.gov)
CHALLENGE: Because specific treatment information for patients in the California Cancer Registry is contained in an unstructured free-text format and manual review is laborious, the information is infrequently used. (cdc.gov)
RESULTS: Manual review of 24,845 text field records associated with 17,310 patients diagnosed with stage IV NSCLC from 2012 to 2014 found specific treatment information for 78% of patients. (cdc.gov)
Findings indicated that there has been variable utilization of treatments and almost a third (31.7%) of patients did not receive systemic treatment. (cdc.gov)

Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases. (targetedonc.com)
Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms. (stanford.edu)

Most of the guidelines recommend offering annual screening with low-dose computed tomography (LDCT) scanning to patients aged 50 to 80 years who have at least a 20 pack-year smoking history and either continue to smoke or have quit within the past 15 years. (medscape.com)
We aimed to investigate the ability of Radiomics applied to computed tomography (CT) in predicting PD-L1 expression in patients with advanced NSCLC. (uniroma1.it)

Conclusions: The current study demonstrated that the effect of first-line EGFR-TKIs was similar to that of platinum-based chemotherapy in patients with uncommon EGFR-mutant NSCLC. (umn.edu)

That compares to 22% for patients treated withhyperfractionated radiation therapy alone. (cancernetwork.com)
In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. (iaslc.org)
The results were comparable but slightly better among patients who had not received prior therapy versus those who were previously treated. (oncnursingnews.com)
Pembrolizumab, which is already approved for patients with advanced melanoma, received an FDA breakthrough therapy designation in October 2014 for patients with EGFR -negative and ALK -rearrangement-negative NSCLC whose disease has progressed on or following platinum-based chemotherapy. (oncnursingnews.com)
When assessing OS by therapies, median OS was similar in HIC-C and HIC-H patients (median 12.8 vs 15.3 mo, respectively) for ICI + combination therapy in the first line. (bmj.com)
Is Systemic Therapy Underused in NSCLC Patients Undergoing Pneumonectomy? (medpagetoday.com)
We very often have these situations where there is an oligoprogression, and by treating a single symptomatic lesion, you may get the patient in a very good place and may continue initial therapy. (medscape.com)
Please think really carefully and weigh all factors, from the patient, the toxicity, and the benefit, before changing the initial systemic therapy. (medscape.com)
Make sure you've gotten everything out of that first-line therapy and that it will be continued as long as possible, as long as you and the patient have concluded that there's benefit. (medscape.com)
This current approval is based on data from ALEX (NCT02075840), a randomized, multi-center, open-label, active-controlled trial conducted in 303 patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease. (fda.gov)
Thirty of these patients received EGFR-TKIs and 40 received platinum-based chemotherapy as first-line therapy. (umn.edu)
The study revealed that combining pembrolizumab with chemo-therapy in patients with previously untreated metastatic squamous NSCLC improved OS, PFS, and PFS-2, increased ORR, and longer duration of respons than placebo plus chemotherapy. (bpno.no)
Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study. (stanford.edu)
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. (stanford.edu)
The fixed model was validated in an independent cohort, detected patients with cancer earlier than standard approaches and could be used to monitor response to therapy. (nature.com)
as a 2nd-line therapy for ALK-positive NSCLC. (wikipedia.org)
As part of the FABREC study, Julia Wong, M.D., of the Dana-Farber Brigham Cancer Center in Boston, and colleagues found that patients with breast cancer who undergo implant-based reconstruction immediately following mastectomy and receive a shorter course of radiation therapy experience similar outcomes to patients who receive a conventional course of radiation. (msdmanuals.com)
The researchers found that patients receiving the short course and those receiving the conventional course of radiation therapy experienced comparable outcomes. (msdmanuals.com)
FASTRACK II is the first multicenter clinical trial of a nonoperative therapy for patients with primary kidney cancer. (msdmanuals.com)

The current patients' selection might be changed by discrimination of acquired resistance-related molecules in patients with NSCLC treated with an EGFR-TKI. (iiarjournals.org)
Summary of patients exhibiting acquired resistance to gefitinib. (iiarjournals.org)

Eight patients with NSCLC were rechallenged with ICI monotherapy and 3 were rechallenged with ICI in combination with chemotherapy. (targetedonc.com)

Patients were randomized 1:1 to receive alectinib 600 mg orally twice daily (n=152) or crizotinib 250 mg orally twice daily (n=151). (fda.gov)
Among the 43 patients with measurable CNS lesions on baseline brain scans, the CNS ORR, assessed by BIRC neuro-radiologist, was 81% (95% CI: 58, 95) in the alectinib arm and 50% (95% CI: 28, 72) in the crizotinib arm. (fda.gov)
Among patients with measurable CNS lesions and a CNS response, the proportion of patients with a CNS response duration of ≥12 months was 59% in the alectinib arm and 36% in the crizotinib arm. (fda.gov)
Patients treated with ALUNBRIG were also shown to have less disease progression than those treated with crizotinib. (patientworthy.com)
Crizotinib in Patients With MET-Amplified NSCLC. (cdc.gov)

This activity is intended for oncologists, nurse practitioners, physician assistants, and other members of the interprofessional team who manage oncology patients in the community setting. (medscape.org)
Overall, approximately 80% of patients were from community oncology practices and approximately 20% were from academic centers. (ascopost.com)
Necitumumab is targeted at EGFR so it makes sense that the drug is active in patients with the receptor," said lead author Luis Paz-Ares, MD, chief of medical oncology at the University Hospital 12 De Octubre in Madrid, Spain. (cancertherapyadvisor.com)
CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. (cancertherapyadvisor.com)

Results of the HIC test may help determine patient prognosis and appropriate personalized regimens. (bmj.com)
RESULTS: CD4-Eff cells, CD8-Eff cells and M1 macrophages were the most abundant immune cells invading the tumour cell compartment and indicated a patient group with a favourable prognosis in the cluster analysis. (lu.se)

Among the total of 5,594 patients with NSCLC included in the analysis, 795 (14.2%) were never-smokers, 3,308 (59.1%) were former smokers, and 1,491 (26.7%) were current smokers at time of diagnosis. (ascopost.com)
METHODS: Liquid biopsy analysis was requested by the referral physician in 121 NSCLC patients at diagnosis and was performed using a sensitive Next Generation Sequencing assay. (bioncology.gr)
Patients must have a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since. (stanford.edu)

Surgery (radiation if the patient is not a surgical candidate), with or without adjuvant chemotherapy based on risk factors, for stages IB and II is generally appropriate. (medscape.com)

Taken together, these results suggest that CAFs-derived exosomes confer cisplatin resistance of NSCLC cells through transferring miRNA-130a and that PUM2 is a critical factor for packaging miRNA-130a into exosomes. (dovepress.com)
This study indicates that CAFs-derived exosomal miRNA-130a may be a potential therapeutic target for cisplatin resistance in NSCLC. (dovepress.com)
Patients were randomly assigned 1:1 to receive gemcitabine 1250 mg/m 2 intravenously (IV) on days 1 and 8 plus cisplatin 75 mg/m 2 IV on day 1 with or without necitumumab 800 mg IV on days 1 and 8, every 21 days for a maximum of 6 cycles. (cancertherapyadvisor.com)

One patient treated with radiationtherapy alone had fatal esophageal toxicity. (cancernetwork.com)
Patients receiving chemoimmunotherapy who did not experience progression could receive necitumumab alone until disease progression or unacceptable toxicity. (cancertherapyadvisor.com)
Brian Stuglik, the company's CEO, said that the currently available alternative for KRAS mutant NSCLC patients are less effective and are often associated with toxicity and resistance issues. (biopharmajournal.com)

Additionally, CAFs-derived exosomes were taken up by NSCLC cells. (dovepress.com)

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic. (bpno.dk)
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic. (bpno.no)

Adenocarcinoma is the most common type of NSCLC. (macmillan.org.uk)
Adenocarcinoma was the independent predictive factor for PFS in uncommon EGFR-mutant NSCLC patients treated with first-line EGFR-TKIs. (umn.edu)

Methods: By applying texture analysis, we retrospectively analyzed 72 patients with advanced NSCLC. (uniroma1.it)
Methods: We retrospectively enrolled 504 patients with EGFR-mutant NSCLC. (umn.edu)

Adverse reactions that led to alectinib discontinuation in 1% or more of patients were renal impairment, hyperbilirubinemia, increased alanine aminotransferase, and increased aspartate aminotransferase. (fda.gov)
The drug's sales are growing from continued strong momentum in metastatic indications, including some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma cancers, and a rapid uptake across recent earlier-stage launches. (zacks.com)

For patients who have KRAS G12C, in the randomized trial that has been done so far, over docetaxel, you get, again, a doubling of response. (medscape.com)
When you do switch, try to give the most effective regimen that you have, which would be docetaxel with ramucirumab, or for patients with KRAS G12C, giving adagrasib or sotorasib at this point. (medscape.com)

Professor Siow Ming Lee (UCL Cancer Institute and UCL Hospitals), who chaired the study Steering Committee and conceptualized the study design, said: 'For over two decades, clinical trials have failed to provide significant therapeutic benefits to older NSCLC patients with poor health who are unfit for standard platinum doublet chemotherapy. (news-medical.net)

The prospective phase 3 LungART trial now demonstrated that PORT cannot be recommended as a standard of care in all completely resected stage IIIA N2 NSCLC patients [1]. (sense-studios.com)
To evaluate the value of PORT in completely resected stage IIIA N2 NSCLC patients, the phase 3 LungART trial was developed. (sense-studios.com)
The phase II expansion portion of the study will enroll around 66 patients, divided into two cohorts. (zacks.com)

As stated by the investigators, "The introduction of immune checkpoint inhibitors has transformed the care of advanced NSCLC. (ascopost.com)
The investigators concluded, "This cohort study found that, among patients with advanced NSCLC, the uptake of immune checkpoint inhibitors after [FDA] approval was rapid across all age groups. (ascopost.com)
Background A proteomic Host Immune Classifier (HIC) was developed that identifies chronic inflammatory disease state for patients diagnosed with NSCLC. (bmj.com)
CONCLUSION: We present a unique spatial profile of the in situ immune cell landscape in NSCLC as a publicly available data set. (lu.se)

However, more than 40% of advanced stage NSCLC patients are in poor health and are often elderly with significant medical co-morbidities. (news-medical.net)
Conclusions OS differed significantly in HIC-C vs HIC-H patients in the overall population and amongst advanced stage patients. (bmj.com)
Part two has now been released, and it focuses on patients with stage IV NSCLC with driver alterations. (lcfamerica.org)
In our summary box, "The Bottom Line," some of the recommendations, such as 1.7 ["For patients with stage IV NSCLC and driver alterations in EGFR"], are based on low-quality evidence. (lcfamerica.org)
Therefore, PORT cannot be recommended as a standard of care in all completely resected stage IIIA N2 NSCLC patients. (sense-studios.com)
This has become a viable and effective option for patients with early-stage NSCLC who are not surgical candidates and in those with significant co-morbidities. (medscape.com)
With chemotherapy for stage I or II NSCLC, the goal is to complete four cycles. (medscape.com)
Cancer Center (NCCN) guidelines for stage IV NSCLC. (cdc.gov)

Your healthcare provider will perform a test to make sure ENHERTU is right for you ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. (studylib.net)
Seventy patients from four centers who were diagnosed with HPV-positive cervical cancer and treated with CRT were enrolled in the study and followed for just over two years. (msdmanuals.com)

The records were of patients aged 18 years or older who were diagnosed with advanced or metastatic NSCLC between 2016 and 2021 who were treated with frontline ICI. (targetedonc.com)

Anatomy5

Organisms2

Diseases19

Chemicals and Drugs49

Analytical, Diagnostic and Therapeutic Techniques and Equipment60

Psychiatry and Psychology1

Phenomena and Processes23

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena1

Humanities1

Information Science1

Health Care26

Geographicals1

Mutations24

Treated with chemotherapy1

20231

Mutation16

Immunotherapy14

Tumors19

T790M9

Lung58

Survival20

Metastatic NSCLC whose1

20221

Osimertinib7

IIIB3

Efficacy5

Resectable NSCLC1

Treatment50

Metastases2

Computed tomography2

Chemotherapy in patients1

Therapy19

Acquired Resistance2

Monotherapy1

Crizotinib5

Oncology4

Prognosis2

Diagnosis3

Adjuvant Chemotherapy1

Cisplatin3

Toxicity3

Additionally1

BestPractice Nordic2

Adenocarcinoma2

Methods2

Renal2

KRAS G12C2

Clinical trials1

Phase3

Immune4

Stage8

Study2

20211